Ricevi le ultime notizie sulle azioni Cogent Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di COGT

Ultime notizie per

COGENT BIOSCIENCES INC

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Cogent Biosciences Inc

Earnings

Press Releases

Cogent Biosciences Reports First Quarter 2025 Financial Results

News

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Financing

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Markets

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cogent Biosciences Reports Recent Business Highlights and  Second Quarter 2025 Financial Results

Health Care

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Small Cap

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COGT

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Biohaven

Cidara Therapeutics

Celcuity

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

89bio

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

MannKind

NuCana

Arcus Biosciences

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Stoke Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Raymond James

Guggenheim

JP Morgan

HC Wainwright & Co.

Citigroup

Comments

Cogent Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO